Skip to main content
. 2021 Sep 8;70(11):2196–2204. doi: 10.1136/gutjnl-2020-323931

Figure 3.

Figure 3

Proposed algorithm of where duodenal mucosal remodelling might fit in the current management of T2D. DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, haemoglobin A1c; SGLT2i, sodium-glucose cotransporter 2 inhibitor; SU, sulfonylurea derivative; T2D, type 2 diabetes.